Published August 31, 2015
| Version v1
Journal article
Open
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein
Contributors
Data curator:
Description
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8
+
T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.
Files
JVirol.89.16.8651-8656.pdf
Files
(1.9 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:e4c37db173967b27ed16e842cc633395
|
1.9 MB | Preview Download |
Additional details
Biodiversity
- Host of
-
(BALB/c mice) → (Middle East respiratory syndrome coronavirus, MERS-CoV)(BALB/c mouse) → (Middle East respiratory syndrome coronavirus, MERS-CoV)(dromedary camels) → (Middle East respiratory syndrome coronavirus, MERS-CoV)